1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Neuromodulation Technologies - A Strategic Perspective (TechVision) 

Neuromodulation Technologies - A Strategic Perspective (TechVision) 

  • February 2016
  • -
  • Frost & Sullivan
  • -
  • 62 pages

Summary

Table of Contents

Neuromodulation Technologies - A Strategic Perspective (TechVision) : Evaluating Technology's Role in Driving Strategic Transformation within Global Neuromodulation Industry

Over the past decade, global industry leaders offering neuromodulation technologies have been largely successful in implementing large scale value stream transformation programs in setting a mature cost-to-serve model. However, understanding the gaps between OEM initiatives in delivering value to care payers and payer demands have been limited. This research service offers a strategic perspective on the industry, analyzing the gaps between technology push-pull factors that are poised to enable OEMs sustain both volume growth and margin. This research also examines how OEMs can shift from a value-to-cost model to a value-to-serve business model, which plays a lead role in delivering personalized value to healthcare payers and care providers.

Key Findings

There is a significant demand for research on cardiovascular disorders, where existing participants in the market invest significant resources focusing on generating sufficient clinical evidence for conditions such as arrhythmia, ischemia and heart failure.

The recent focus of top OEMs on single-source suppliers helps in improving operational efficiency, and balancing quality, delivery, and cost. However, translation of cost-reduction efforts to payers and driving reimbursement is critical for top-line growth.

Findings of the benchmarking clearly suggest that there is a shift toward minimally-invasive and connected health technologies that enable patients to take therapy at the convenience of the physicians office or at home. Percutaneous stimulation technologies are a step in this direction.

To sustain profitable growth, OEMs must align strategic intent towards building a value-driven business model that is well differentiated in its offerings to mature markets, where cost efficiencies are transferred across the value stream.

Our analysis evaluates the real-world examples, and emerging business models where customer value is driven by early adoption and successful integration of social, mobile, analytics and networking, which is key to driving efficiency across the value stream.

Acquisitions enable OEMs to drive market growth and the forward integration moves of existing single-source suppliers could pose a threat to the profitability of OEMs.

Entry of minimal/non-invasive technologies with strong IP, regulatory approvals (CE/TGA) and strong clinical data for chronic lifestyle disorders would drive further consolidation within the market by acquisitions by OEMs, giving exit to VC/PE firms.

While OEMs continue to gain ground in establishing safety/efficacy for existing products in mature markets, their VC counterparts continue to invest early in technologies, enabling the launch of new products/services for existing markets.

OEMs have been successful in implementing large-scale value stream transformation programs to single-source suppliers; this is expected to reduce the overall cost of activities across the value chain, with a mature cost-to-serve model.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • $ 6500
  • Industry report
  • February 2017
  • by P&S Market Research

Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • March 2017
  • by Transparency Market Research

Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; ...

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.